VR 588

Drug Profile

VR 588

Alternative Names: VR588

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Vectura
  • Developer Imperial College of Science, Technology and Medicine; Vectura
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors; TRPV1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma
  • Preclinical Inflammation

Most Recent Events

  • 23 Nov 2016 Vectura plans a phase I/IIa trial of VR 588 in Respiratory tract disorders
  • 19 Oct 2016 Vectura completes a phase I trial in Asthma in United Kingdom (NCT02740049)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top